press release

February 7, 2019

− Achieved Fourth Quarter 2018 ONPATTRO® Global Net Product Revenues of $12.1 Million, with Over 200 Patients on Commercial Product in U.S. and EU as of Year End 2018 – − Obtained Regulatory Alignment on APOLLO B Phase 3 Study of Patisiran in ATTR Amyloidosis with Cardiomyopathy and Initiated HELIOS A Phase 3 Study to Advance Vutrisiran to Market, Supporting Plan ...

press release

January 7, 2019

− Achieved Fourth Quarter 2018 ONPATTRO Unaudited Global Net Product Revenues of $11 12 Million – − Over 200 Patients on Commercial ONPATTRO in U.S. and EU from Launch Through Year End 2018 – − Maintained Strong Balance Sheet with Unaudited Year End Cash and Investments Balance of Approximately $1.1 Billion – CAMBRIDGE, Mass. (BUSINESS WIRE) Jan. 7, 2019 Alnylam ...

press release

December 6, 2018

− In 2019, Alnylam Will Continue ONPATTRO™ Global Launch and Advance Late Stage Pipeline of Wholly Owned and Partnered Programs with: Five Phase 3 Programs; Three Phase 3 Program Readouts; and Two New Drug Application (NDA) Filings – − Initiates Rolling Submission of Givosiran NDA to U.S. Food and Drug Administration (FDA) – − Initiates HELIOS A Phase 3 Study of ...

capella

December 5, 2018

On December 6th, 2018, we will be hosting an R&D Day in New York City where Alnylam management and key opinion leaders will discuss our late stage clinical efforts, in addition to next wave programs and platform advances.  Scroll down to see the R&D Day agenda and links to the presentations.  Learn more about our science and the science of RNAi.  ...

press release

November 29, 2018

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 29, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Company’s website, www.alnylam.com, on the morning of December 6, 2018. Alnylam management and key opinion leaders will discuss late stage clinical ...

press release

November 26, 2018

-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection Subject dosing commenced SAN FRANCISCO & CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 26, 2018 Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR 2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic ...

press release

November 7, 2018

− Obtained FDA and EMA Approvals of ONPATTRO™ (patisiran) – the First Ever RNAi Therapeutic – and Launched in U.S. and EU − − Received 125 U.S. Patient Start Forms in First Seven Weeks of ONPATTRO Launch − − Reported Positive Topline Interim Analysis Results from ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyrias − − Advanced ...

press release

September 14, 2018

− Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy – − In Exploratory Post Hoc Analysis, Reduction of All Cause Mortality and Hospitalization Was Observed in Patients Treated with Patisiran – CAMBRIDGE, Mass. (BUSINESS WIRE) Sep. 14, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced ...

press release

August 10, 2018

− First and Only FDA approved Treatment Available in the United States for this Indication – − ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients – − Improvement in Specified Measures of Quality of Life and Disease Burden Demonstrated Across Diverse, Global Patient Population – − Alnylam to Host ...

news

August 3, 2018

Alnylam President Barry Greene has been named to the PharmaVoice 100 for 2018.  Barry was selected "for being an RNAi champion." From PharmaVoice: "Alnylam President Barry Greene has played a pivotal role in leading the company's 15 year journey to translate the raw and Nobel Prize winning science of RNA interference (RNAi) into a clinically validated platform and a potential new ...